Satellos Bioscience (MSLE) Depreciation & Amortization (CF) (2025 - 2026)
Satellos Bioscience (MSLE) posted quarterly Depreciation & Amortization (CF) of $1000.0 for Q1 2026, little changed year-over-year from $1000.0 in Q1 2025, and little changed quarter-over-quarter from $1000.0 in Q1 2025.
Satellos Bioscience (MSLE) Depreciation & Amortization (CF) (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Depreciation & Amortization (CF) for 2 consecutive years, with $1000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $1000.0; the TTM figure through Mar 2026 stood at $2000.0 (changed N/A YoY), while the FY2025 annual figure was $4000.0, changed N/A from the prior year.
- Depreciation & Amortization (CF) held at $1000.0 in Q1 2026 per MSLE's latest filing, from $1000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1000.0 in Q1 2025 and bottomed at $1000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Satellos Bioscience | 206.75 Mn | 206.75 Mn | - | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |